[Skip to Content]
[Skip to Content Landing]
December 1992

Immunotherapy With a Tumor-Infiltrating Lymphocyte Clone, Soluble Antigen, and Cyclophosphamide

Author Affiliations

From the Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston.

Arch Surg. 1992;127(12):1417-1423. doi:10.1001/archsurg.1992.01420120051009

• A tumor-specific cytotoxic T-lymphocyte clone derived from bulk cultures of tumor-infiltrating lymphocytes attenuated the outgrowth of methylcholanthrene (MCA)—induced fibrosarcomas in C3H/HeJ mice. In 4-hour chromium 51–release assays, bulk cultures of tumor-infiltrating lymphocytes showed nonspecificity for MCA-induced tumors (MCA-F, MCA-D, MCA-SP), YAC-1, and EL-4. In contrast, a cytotoxic T-lymphocyte—cloned line specifically killed MCA-F, but not MCA-D or MCA-SP. Cytotoxic T-lymphocyte line 8 protected syngeneic hosts in local and systemic adoptive transfer assays. Hosts bearing 4-day-established MCA-F tumor cells received single agents or combinations of isoelectrophoretically purified butyl alcohol—extracted tumor-specific transplantation antigen (1 μg/wk), cyclophosphamide (20 mg/kg on days 4 and 11), and/or cytotoxic T-lymphocytes (1 × 107 cells on days 7 and 14). While the mean tumor diameter was 11.6±1.3 mm in untreated hosts or after single treatments, the combination of tumor-specific transplantation antigen and cyclophosphamide along with the cytotoxic T-lymphocyte clone resulted in tumor diameters of 1.8±0.5 mm. The triple combination prolonged host survival from 39.6±1.6 to 57.2±4.7 days compared with antigen and cyclophosphamide treatment.

(Arch Surg. 1992;127:1417-1423)